Bildkälla: Stockfoto

BioInvent: New Orphan Drug Designation in Lymphoma - Redeye

Redeye views the orphan drug designation for BI-1206 in follicular lymphoma as a further confirmation of being on the right path in lymphoma.

Redeye views the orphan drug designation for BI-1206 in follicular lymphoma as a further confirmation of being on the right path in lymphoma.
Börsvärldens nyhetsbrev
ANNONSER